SVNS — Solvonis Therapeutics Income Statement
0.000.00%
Last trade - 00:00- £17.70m
- £16.06m
- 21
- 11
- 84
- 28
Annual income statement for Solvonis Therapeutics, fiscal year end - December 31st, GBP millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|
| Period Length: | 7 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final |
| Revenue | ||||
| Total Revenue | 0.219 | 0.542 | 0.587 | 0 |
| Cost of Revenue | ||||
| Gross Profit | 0.101 | 0.3 | 0.258 | 0 |
| Selling / General / Administrative Expenses | ||||
| Depreciation and Amortization | ||||
| Unusual Expense / Income | ||||
| Other Operating Expenses | ||||
| Total Operating Expenses | 1.17 | 3.24 | 3.7 | 1.38 |
| Operating Profit | -0.946 | -2.7 | -3.12 | -1.38 |
| Total Net Non Operating Interest Income / Expense | ||||
| Net Income Before Taxes | -0.954 | -2.71 | -3.12 | -1.45 |
| Provision for Income Taxes | ||||
| Net Income After Taxes | -0.954 | -2.71 | -3.12 | -1.45 |
| Net Income Before Extraordinary Items | ||||
| Extraordinary Items | ||||
| Net Income | -0.954 | -2.71 | -3.12 | -1.59 |
| Income Available to Common Shareholders Excluding Extraordinary Items | ||||
| Income Available to Common Shareholders Including Extraordinary Items | ||||
| Diluted Net Income | -0.954 | -2.71 | -3.12 | -1.59 |
| Diluted Weighted Average Shares | ||||
| Basic EPS Including Extraordinary Items | ||||
| Diluted EPS Including Extraordinary Items | ||||
| Diluted EPS Excluding Extraordinary Items | ||||
| Normalised Income Before Taxes | ||||
| Normalised Income After Taxes | ||||
| Normalised Income Available to Common Shareholders | ||||
| Diluted Normalised EPS | -0.009 | -0.026 | -0.022 | -0.001 |
| Dividends per Share |